Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Breast 1

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC) 2Severe Acute Respiratory Syndrome 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Neoadjuvant Therapy \High Risk Prostate Cancer 1COVID-19 1Alopecia 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
proxalutamide × Genitourinary × Clear all
NCT03899467 2024-02-12

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Suzhou Kintor Pharmaceutical Inc,

Phase 2 Completed
61 enrolled 12 charts
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT04446429 2021-12-10

Anti-Androgen Treatment for COVID-19

Applied Biology, Inc.

Phase NA Completed
268 enrolled 8 charts
Genitourinary

COVID-19, Alopecia, Prostatic Hyperplasia, Prostatic Neoplasms, Severe Acute Respiratory Syndrome

NCT05076851 2021-10-13

Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy(ADT)for High Risk Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
2 enrolled
Genitourinary

Neoadjuvant Therapy \High Risk Prostate Cancer

NCT02826772 2020-03-17

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Suzhou Kintor Pharmaceutical Inc,

Phase 1 Completed
40 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡